Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review.
Costs and cost-effectiveness of HIV early infant diagnosis in low- and middle-income countries: a scoping review.
复制标题
低收入国家和中等收入国家的艾滋病毒早期婴儿诊断的成本和成本效益：范围审查。
DOI：
10.1186/s40249-022-01006-7
复制
发表时间：
2022-07-15
影响因子：
8.1
通讯作者：
中科院分区：
文献类型：
--
作者：
全球儿科人类免疫缺陷病毒 (HIV) 应对工作的持续进展取决于及时识别和护理感染艾滋病毒的婴儿。随着各国逐步扩大艾滋病毒婴儿早期诊断 (EID) 的改进，需要进行经济评估来为项目设计和实施提供信息。本次范围界定审查旨在总结现有证据并讨论 HIV EID 成本和成本效益分析的实际影响。我们系统地检索了 2008 年 1 月至 2021 年 6 月期间出版的低收入和中等收入国家 HIV EID 经济分析的书目数据库（Embase、MEDLINE 和 EconLit）和灰色文献。我们提取了有关单位成本、成本节省和增量成本效益比以及与健康和 HIV EID 护理过程相关的结果的数据，并以叙述和表格格式总结了结果。我们将单位成本换算为 2021 美元，以便更轻松地比较不同研究的成本。经过对 1278 条记录的标题和摘要筛选以及对 99 条记录的全文审查后，我们纳入了 29 项研究：17 项成本分析和 12 项基于模型的成本效益分析。即时 EID 测试的单位成本为 21.46–51.80 美元，实验室 EID 测试的单位成本为 16.21–42.73 美元。所有成本效益分析均表明至少一项干预措施被评估为具有成本效益。大多数研究报告了 EID 测试策略的成本；然而，很少有研究以相同的方式评估相同的干预措施或报告成本，这使得比较不同研究的成本具有挑战性。 HIV 感染儿童的具体成本和结果的数据有限，以及成本效益模型研究的结构异质性限制了 HIV EID 经济分析的普遍性。 HIV EID 的现有成本和成本效益证据虽然在不同研究中无法直接比较，但涵盖了广泛的干预措施，并表明大多数旨在改善 EID 的干预措施具有成本效益或节省成本。需要进一步研究了解在现实环境中提供 EID 服务的成本和收益。在线版本包含可在 10.1186/s40249-022-01006-7 获取的补充材料。
Continuing progress in the global pediatric human immunodeficiency virus (HIV) response depends on timely identification and care of infants with HIV. As countries scale-out improvements to HIV early infant diagnosis (EID), economic evaluations are needed to inform program design and implementation. This scoping review aimed to summarize the available evidence and discuss practical implications of cost and cost-effectiveness analyses of HIV EID. We systematically searched bibliographic databases (Embase, MEDLINE and EconLit) and grey literature for economic analyses of HIV EID in low- and middle-income countries published between January 2008 and June 2021. We extracted data on unit costs, cost savings, and incremental cost-effectiveness ratios as well as outcomes related to health and the HIV EID care process and summarized results in narrative and tabular formats. We converted unit costs to 2021 USD for easier comparison of costs across studies. After title and abstract screening of 1278 records and full-text review of 99 records, we included 29 studies: 17 cost analyses and 12 model-based cost-effectiveness analyses. Unit costs were 21.46–51.80 USD for point-of-care EID tests and 16.21–42.73 USD for laboratory-based EID tests. All cost-effectiveness analyses stated at least one of the interventions evaluated to be cost-effective. Most studies reported costs of EID testing strategies; however, few studies assessed the same intervention or reported costs in the same way, making comparison of costs across studies challenging. Limited data availability of context-appropriate costs and outcomes of children with HIV as well as structural heterogeneity of cost-effectiveness modelling studies limits generalizability of economic analyses of HIV EID. The available cost and cost-effectiveness evidence for EID of HIV, while not directly comparable across studies, covers a broad range of interventions and suggests most interventions designed to improve EID are cost-effective or cost-saving. Further studies capturing costs and benefits of EID services as they are delivered in real-world settings are needed. The online version contains supplementary material available at 10.1186/s40249-022-01006-7.
登录
查看更多内容
影响因子：
16.1
作者：
Frank, Simone C.;Cohn, Jennifer;Ciaranello, Andrea L.
通讯作者：
Ciaranello, Andrea L.
影响因子：
3.8
作者：
Jani, Ilesh V.;Meggi, Bindiya;Peter, Trevor F.
通讯作者：
Peter, Trevor F.
影响因子：
6
作者：
Dunning L;Gandhi AR;Penazzato M;Soeteman DI;Revill P;Frank S;Phillips A;Dugdale C;Abrams E;Weinstein MC;Newell ML;Collins IJ;Doherty M;Vojnov L;Fassinou Ekouévi P;Myer L;Mushavi A;Freedberg KA;Ciaranello AL
通讯作者：
Ciaranello AL
影响因子：
3.8
作者：
Bourne, David E.;Thompson, MaryLou;Myers, Jonny E.
通讯作者：
Myers, Jonny E.
影响因子：
6.4
作者：
Francke, Jordan A.;Penazzato, Martina;Ciaranello, Andrea
通讯作者：
Ciaranello, Andrea